An innovative immunoassay, called enzyme-linked immunoabsorbant assay (ELISA) Reverse, based on a new conformation of the solid phase, was developed. The solid support was expressly designed to be immersed directly in liquid samples to detect the presence of protein targets. Its application is proposed in those cases where a large number of samples have to be screened simultaneously or when the simultaneous detection of different proteins is required. As a first application, a quantitative immunoassay for Cry1AB protein in genetically modified maize was optimized. The method was tested using genetically modified organism concentrations from 0.1 to 2.0%. The limit of detection and limit of quantitation of the method were determined as 0.0056 and 0.0168 (expressed as the percentage of genetically modified organisms content), respectively. A qualitative multiplex assay to assess the presence of two genetically modified proteins simultaneously was also established for the case of the Cry1AB and the CP4EPSPS (5-enolpyruvylshikimate-3-phosphate synthase) present in genetically modified maize and soy, respectively.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Genetically modified organisms (GMOs);
enzyme-linked immunoabsorbant assay (ELISA) Reverse;
Document Type: Research Article
Biotechnology & GMOs Unit, Institute for Health and Consumer Protection (IHCP), European Commission, DG-Joint Research Centre (JRC), Via. E. Fermi 1, 201020 Ispra (VA), Italy
DISTAAM, Università degli Studi del Molise, Via De Sanctis, 86100, Campobasso, Italy
September 1, 2006
More about this publication?